Dr. Jänne is a Translational Thoracic Medical Oncologist at the Dana Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, MA. He is the Director of the Lowe Center for Thoracic Oncology and the Scientific Co-Director of the Belfer Institute for Applied Cancer Sciences also in Boston, MA. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania in Philadelphia, PA, Dr. Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital in Boston, MA. He subsequently completed a fellowship training at the Dana Farber Cancer Instute/Massachusetts General Hospital combined program in Medical Oncology in 2001. In 2002, Dr. Jänne earned a Masters Degree in Clinical Investigation from Harvard University.
Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. Dr. Jänne has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work has led to the development of several clinical trials. In addition, he led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib (AZD9291) which was recently approved by the Food and Drug Administration. Dr. Jänne has received several awards for his research including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. In 2008, he was elected as a member to the American Society of Clinical Investigation. Dr. Jänne is also the recipient of the 2010 American Association of Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.
- (Activity Chair)
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute